Vanguard Global Advisers’s KALA BIO KALA Stock Holding History

Vanguard Global Advisers’s Portfolio KALA Stock Details KALA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-17	Closed	-$144	–	3694
2026 Q1	$144	Buy	+17	New	+$360	﹤0.01%	3673

Other funds holding KALA

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Vanguard Global Advisers's KALA Position: Q2 2026 in Review

Vanguard Global Advisers sold out of KALA BIO (KALA) in Q2 2026, closing a stake of 17 shares — an estimated $144 sold.

Vanguard Global Advisers first reported a position in KALA in Q1 2026 and held it in 1 quarter. The position peaked at $144 in Q1 2026. 14 funds tracked by Wall St. Rank hold KALA as of Q2 2026.

Vanguard Global Advisers reported no remaining KALA BIO position as of Q2 2026 after selling out during the quarter.
Vanguard Global Advisers sold 17 KALA BIO shares in Q2 2026, an estimated $144.
Vanguard Global Advisers first reported a position in KALA BIO in Q1 2026 and held it in 1 quarter.
Vanguard Global Advisers's KALA BIO position peaked at $144 in Q1 2026.
14 funds tracked by Wall St. Rank held KALA BIO as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.